• Effect of Interferon Gamma as a Treatment for Post-aggressive Immunosuppression in Intensive Care Units, a Randomized Bayesian Double-blind Controlled Trial Versus Placebo

  NCT06694740

  RecruitingInterventionalPhase 2Phase 3Updated Jul 6, 2026
• Human Recombinant Interferon Gamma in the Treatment of Ventilator-acquired Pneumonia in ICU Patients

  NCT05843786

  RecruitingInterventionalPhase 3Updated Jul 6, 2026
• The Effects of Interferon-gamma on Sepsis-induced Immunoparalysis

  NCT01649921

  CompletedInterventionalPhase 3Updated Sep 29, 2017
• Treatment of Non-Tuberculous Mycobacterial Infections With Interferon Gamma

  NCT00001318

  CompletedInterventionalPhase 2Updated Mar 4, 2008
• GM-CSF to Decrease ICU Acquired Infections

  NCT02361528

  CompletedInterventionalPhase 3Updated May 27, 2026
• Kinetics of INF-γ Production in Intensive Care Patients

  NCT06549374

  RecruitingObservationalUpdated May 19, 2026

ClinicalTrials.gov ID

NCT06774235

Lead Sponsor

University Hospital, LimogesOTHER

Overall Status

Recruiting

Study Type

Interventional

Phase

Phase 3

Enrollment

326Estimated

Last Update Posted

Nov 20, 2025Actual

Start Date

Jul 9, 2025Actual

Primary Completion Date

Oct 9, 2028Estimated

Completion Date

Oct 9, 2028Estimated

Official Title

Prevention of Secondary Infections by Interferon Gamma in ICU-acquired Sustained Immune-suppression: a Randomized Trial

Brief Summary

The goal of this clinical trial is to demonstrate the benefit of a standardized immunotherapy (Interferon gamma) on the incidence of secondary infections. . It will also learn about the safety of Interferon-gamma. The main questions it aims to answer are:

Does Interferon-gamma:

• reduces the Incidence of secondary infection episodes at three months
• reduces the ICU mortality and at Day 90
• reduces the ICU and hospital length of stay
• induces Biological immune restoration at Day 10
• has cost-consequence and cost-effectiveness

Researchers will compare Interferon-gamma to a placebo (a look-alike substance that contains no drug) to see if Interferon-gamma works to treat sustained immunosuppression .

Participants will:

• Take Interferon-Gamma or a placebo for a maximum of 5 times between day 1 and day 9
• be monitored evety day until their ICU discharge and at day 30, 60 and 90

• Sustained Immunosuppression

• Interferon Gamma 1-b
• Placebo

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Adult patient hospitalized in the ICU for at least 1 week
• Expected length of stay in the ICU greater than 10 days at screening
• At least 1 episode of multiple organ failure, defined as a SOFA ≥ 6 (excluding the respiratory component when related to a neurological failure), during the first 1 week of ICU hospitalization
• Immunosuppression defined as an mHLA-DR < 8000 Ab/c and a lymphopenia < 1000/mm3 within a 96 hours time window
• Patient or the legal representative giving consent must be able to understand the trial in its entirety
• Patient affiliated to the social security system
• For female participants of childbearing potential, agreement to use dual methods of contraception until Day 90
• For male participants with female partners of childbearing potential, agreement to use barrier method of contraception until Day 90.

Exclusion Criteria:

• Uncontrolled secondary infections ongoing at the time of screening
• Participation in another research clinical trial within 30 days
• Chemotherapy / radiation therapy within the last 6 weeks
• Apache II ≥ 30 at screening
• History of autoimmune disease
• Organ or bone marrow transplant
• History of hematologic malignancy
• History of hepatitis C
• HIV stage C within the last 12 months
• Patients under legal protection
• History of or ongoing tuberculosis
• Chronic hepatitis B
• Patients receiving immunosuppressive medications including patient receiving a steroid dose greater than 1mg/kg/day of prednisone equivalent for more than 1 week and patient that have been on corticosteroid for more than 3 months
• Patient with thrombocytopenia below 50,000/mm3
• Patient with traumatic brain and spinal injury
• Pregnancy or breast feeding
• Subjects with a history hypersensitivity to interferon gamma or excipient (Mannitol, Sodium succinate dibasic hexahydrate, Succinic acid, polysorbate 20), known latex hypersensitivity or other interferon
• Hepatic cytolysis with AST/ALT > 5 times ULN (local laboratory)
• Suspected acute pancreatitis with lipase or amylase > 3 times ULN (local laboratory)
• Severe chronic renal failure (eGFR<10 ml/min/1.73m2 CKP-EPI method)
• Acute ECG abnormality such as myocardial infarction or any acute life-threatening ECG abnormalities (e.g: ventricular fibrillation, ventricular tachycardia…)
• Mental state rendering the person giving consent incapable of understanding the trial
• Patient deprived of liberty by judicial or administrative decision
• Patient being the investigator, or any member of the team or relative of the investigator directly involved in the trial, including assistant doctors, pharmacists, nurses, trial coordinators

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

Triple

Lead Sponsor

University Hospital, LimogesOTHER

nvangrunderbeeck@ch-lens.fr0321691088 ext. +33

sami.hraiech@ap-hm.fr+33491965836